SuperworthAlaunos Therapeutics TCRT
- Market cap
- $5.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Alaunos Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $1K−91% | $1K | $4K+0% | $0 | n/a | $2K+100% | $0 | $0 | n/a | $0 | $0 | |
| R&D | $3.7M−54% | $933K−83% | $126K−98% | $180K−97% | $143K−96% | n/a | $347K+175% | $185K+3% | $469K+228% | n/a | $427K+23% | $388K+110% |
| SG&A | $3.6M+9% | $2.4M−17% | $1.6M−49% | $990K−68% | $1M−72% | n/a | $747K−54% | $854K−14% | $718K−29% | n/a | $585K−22% | $564K−34% |
| −$8.7M+5% | −$7.9M−7% | −$1.7M−82% | −$1.2M−85% | −$1.1M−87% | n/a | −$1.1M−37% | −$1M−11% | −$1.2M+3% | n/a | −$1M−7% | −$952K−8% | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$8.5M−4% | −$7.8M−14% | −$1.7M−83% | −$1.1M−87% | −$1.1M−87% | −$742K−91% | −$1.1M−36% | −$1.1M−7% | −$1.2M+3% | −$893K+20% | −$1M−6% | −$952K−9% |
| −$5.30−12% | −$4.90−18% | −$1.05−83% | −$0.71−87% | −$0.70−87% | −$0.46−91% | −$0.67−36% | −$0.63−11% | −$0.55−21% | −$0.40−13% | −$0.59−12% | −$0.41−35% | |
| 1.6M+12% | 1.6M+8% | 1.6M+0% | 1.6M+0% | 1.6M+0% | 1.6M+0% | 1.6M+0% | 1.7M+5% | 2.2M+36% | 2.3M+45% | 1.9M+22% | 2.4M+45% |
EPS, diluted: 11 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY09: share-days: the 12-month average less the 9-month, weighted by days. 14 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x15).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Alaunos Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TCRTAlaunos Therapeutics | $5.8M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| Peer median | $47.8M | 13.6× | 14.8× | 1.4× | +15% | 7.6% |
More on Alaunos Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .